Colgate-Palmolive (CL) Stock Analysis 2026: The Quiet Dividend King You're Overlooking

title: "Colgate-Palmolive (CL) Stock Analysis 2026: The Quiet Dividend King You're Overlooking" description: "In-depth Colgate-Palmolive (CL) stock analysis for 2026. Graham Number, Piotroski F-Score, 63-year dividend streak, and honest buy/hold/sell verdict." date: "2026-03-06" category: "Stock Analysis" author: "Poor Man's Stocks" image: "/images/blog/cl-stock-analysis.jpg"

Nobody brags at a dinner party about owning Colgate-Palmolive stock.

It is not sexy. It is not disruptive. It does not have a charismatic CEO doing podcast tours. It makes toothpaste, soap, and pet food. That is it.

And that is exactly why it has raised its dividend for 63 consecutive years.

While flashy tech stocks have come and gone — while even supposed "safe" stocks like AT&T and 3M have stumbled — Colgate-Palmolive has quietly compounded wealth for generations of investors. Every single year since 1963, shareholders have gotten a bigger check.

But at a P/E ratio north of 35, is the Quiet King worth buying at today's prices? Or are you just paying a massive premium for the privilege of owning toothpaste?

Let us find out.

Colgate-Palmolive at a Glance: Key Metrics (March 2026)

| Metric | Value | |---|---| | Stock Price | $92.67 | | Market Cap | $74.28B | | Enterprise Value | $81.44B | | Revenue (FY 2025) | $20.38B | | Net Income (FY 2025) | $2.13B | | EPS (Diluted) | $2.63 | | P/E Ratio | 35.24 | | Forward P/E | 23.88 | | Dividend Per Share | $2.08 | | Dividend Yield | 2.18% | | Payout Ratio | 79.09% | | Book Value Per Share | $0.07 | | Free Cash Flow | $3.63B | | FCF Per Share | $4.53 | | Gross Margin | 60.11% | | Beta | 0.26 | | Consecutive Dividend Growth Years | 63 |

Data sourced from StockAnalysis.com as of March 2026.

The Colgate-Palmolive Moat: Why It Works

Before we get into the valuation math, you need to understand why this company has survived and thrived for over 200 years (yes, Colgate was founded in 1806).

1. Products People Buy Every Day, No Matter What

Recession? People still brush their teeth. Inflation? They still wash their hands. War? They still feed their dogs. Colgate-Palmolive sells non-discretionary consumer staples — products that are the absolute last things people cut from their budgets.

2. Global Reach Most Companies Dream Of

Colgate operates in 200+ countries and territories. About 70% of revenue comes from outside the United States. That is massive geographic diversification. When the U.S. slows, emerging markets in Latin America, Asia, and Africa often pick up the slack.

3. Brand Power You Cannot Replicate

Colgate is the #1 toothpaste brand globally with roughly 40% market share. Hill's Pet Nutrition is a veterinarian-recommended premium brand. Palmolive and Ajax are household names. These brands were not built overnight — they were built over decades of consumer trust.

4. Pricing Power That Beats Inflation

Gross margins above 60% tell you everything. Colgate can raise prices and consumers barely flinch. This is the hallmark of a true economic moat — what Warren Buffett calls a "toll bridge" business.

Revenue and Earnings: Slow and Steady

| Year | Revenue | EPS (Diluted) | FCF | |---|---|---|---| | 2021 | $17.42B | $2.55 | $2.76B | | 2022 | $17.97B | $2.13 | $1.86B | | 2023 | $19.46B | $2.77 | $3.04B | | 2024 | $20.10B | $3.51 | $3.55B | | 2025 | $20.38B | $2.63 | $3.63B |

A few observations:

Revenue growth is modest but consistent — 1.4% in 2025, coming off a stronger 3.3% in 2024. For a mature consumer staples company, this is par for the course. Organic growth (adjusting for currency) has been stronger, typically in the mid-single digits.

The 2025 EPS drop needs context. That $2.63 figure (down 25% from $3.51) was driven by large charges related to Colgate's skin-health business. The company took write-downs on Filorga, a premium skincare brand acquired in 2020 that has underperformed expectations. The core oral care and home care businesses actually grew earnings.

Free cash flow is the real story. FCF of $3.63B grew 2.5% year-over-year and represents a 17.8% FCF margin. This is a cash generation machine. Even in a year where reported earnings dropped, FCF kept climbing. That tells you the underlying business is healthy — the earnings hit was a non-cash write-down.

The 5-year FCF trajectory is impressive: from $2.76B to $3.63B, a 31.5% increase. That cash funds the dividend, buybacks (shares down 1.47% YoY), and debt reduction.

Graham Number Calculation

The Graham Number uses Benjamin Graham's formula:

Graham Number = √(22.5 × EPS × Book Value Per Share)

For Colgate-Palmolive:

EPS (Diluted, TTM) = $2.63
Book Value Per Share = $0.07

Graham Number = √(22.5 × 2.63 × 0.07) Graham Number = √(4.14) Graham Number = $2.03

Wait — $2.03? The stock trades at $92.67!

Here is why the Graham Number does not work for Colgate-Palmolive. The company has spent decades buying back its own shares aggressively. Total treasury stock on the balance sheet is -$28.45B, which has driven total shareholders' equity to just $54 million — essentially zero for a $74B company.

Benjamin Graham designed his formula in an era when companies did not do massive share buybacks. When book value is artificially near zero (or negative), the Graham Number becomes meaningless. This does not mean CL is overvalued — it means the tool breaks for companies with aggressive capital return programs.

You will find the same issue with other buyback-heavy consumer staples companies. The lesson? Always use multiple valuation tools. No single metric tells the whole story. Our Benjamin Graham's 7 Criteria guide explains when to use — and when to ignore — each metric.

A More Useful Valuation Approach: FCF Yield

Since book value is broken for CL, let us use Free Cash Flow Yield instead:

FCF Per Share: $4.53
Stock Price: $92.67
FCF Yield: 4.89%
Price-to-FCF: 20.4x

A 4.89% FCF yield means you are paying about 20.4x free cash flow. For a Dividend King with 60%+ gross margins and consistent growth, that is reasonable — not cheap, but not outrageous. Compare that to the broader S&P 500 average P/FCF of about 25-28x.

DCF-Based Intrinsic Value Estimate

Using conservative assumptions:

Current FCF: $3.63B
Growth Rate: 4% (organic growth + pricing power)
Discount Rate: 8.5% (low beta = lower risk premium)
Terminal Multiple: 22x FCF (premium quality deserves premium multiple)

Year 10 FCF: $3.63B × (1.04)^10 = $5.37B Terminal Value: $5.37B × 22 = $118.2B Discounted back + intermediate cash flows ≈ $90-100 per share

At $92.67, Colgate-Palmolive is trading right around fair value. Not a bargain, but not overpriced when using a DCF model that accounts for quality.

Piotroski F-Score Assessment

The Piotroski F-Score rates financial health from 0-9:

| Criteria | Pass/Fail | Notes | |---|---|---| | Positive Net Income | ✅ Pass | $2.13B net income | | Positive Operating Cash Flow | ✅ Pass | $4.20B operating cash flow | | ROA Increasing | ❌ Fail | ROA declined due to one-time skin-health charges | | Cash Flow > Net Income | ✅ Pass | FCF $3.63B > Net Income $2.13B — excellent earnings quality | | Declining Long-Term Debt | ✅ Pass | LT debt decreased from $7.29B to $6.87B | | Current Ratio Improving | ❌ Fail | Current ratio at 0.83, below 1.0 (common for consumer staples with strong cash flows) | | No Share Dilution | ✅ Pass | Shares decreased 1.47% (active buyback program) | | Gross Margin Improving | ❌ Fail | Gross margin slipped slightly from 60.50% to 60.11% | | Asset Turnover Improving | ✅ Pass | Revenue/assets ratio improved |

Estimated Piotroski F-Score: 6/9 — Solid. The fails are mostly technical (buyback-distorted balance sheet, minor margin changes) rather than fundamental problems. The FCF-over-net-income pass is particularly encouraging — it means the reported earnings decline is misleading and cash generation is healthy.

The Bull Case: A Defensive Fortress

| Bull Case Factors | Details | |---|---| | Ultimate Defensive Stock | Beta of 0.26 — one of the least volatile stocks in the S&P 500 | | 60%+ Gross Margins | Best-in-class among consumer staples. Consistent pricing power. | | Emerging Market Growth | 70% international revenue. Rising middle class in Africa, Asia, Latin America drives oral care adoption. | | 63-Year Dividend Streak | One of the longest active streaks among all U.S. companies. 4% annual growth. | | FCF Machine | $3.63B in free cash flow, growing consistently. Covers dividend + buybacks easily. | | Recession-Proof | CL held up in 2008, 2020, and every downturn in between. Stock barely moved during COVID. | | Hill's Pet Nutrition | Premium pet food segment growing faster than oral care. Pet spending is a secular growth trend. | | Buyback Program | Shares declining 1.5% annually — compounding EPS growth even when revenue is flat |

The bull thesis is simple: "The world is not going to stop brushing its teeth." Colgate owns the global #1 position in oral care, and that position only gets stronger as emerging market consumers trade up from local brands to trusted names.

The low beta means when the market panics, CL tends to hold up. During the 2022 bear market, CL declined only about 10% while the S&P 500 fell 25%. This is the stock you own to sleep at night.

And Hill's Pet Nutrition is an underappreciated growth driver. Americans now spend over $140 billion annually on pets, and premium vet-recommended brands like Hill's Science Diet command significant pricing power. This segment could be a meaningful contributor to organic growth going forward.

The Bear Case: Paying a Premium for Safety

| Bear Case Factors | Details | |---|---| | P/E of 35 Is Expensive | Even forward P/E of 24 is rich for 1-4% revenue growth | | Slow Top-Line Growth | Revenue grew just 1.4% in 2025. Hard to get excited about. | | Currency Headwinds | 70% international means FX translation can erase organic gains entirely in certain years | | Private Label Competition | Store-brand toothpaste and soap at Walmart and Costco pressures volumes | | Filorga Impairment | The $1.4B skincare acquisition has been a drag. Write-downs hit 2025 earnings. Management misjudged the premium skincare market. | | 2.18% Yield Is Low | For an income investor, you can get 4-5% from treasury bonds risk-free | | Payout Ratio at 79% | Not much room for error if earnings stay depressed. Dividend growth could slow. | | Negative Tangible Book Value | -$5.68 TBVPS means the balance sheet has no asset cushion |

The bear case boils down to: "You are paying 35x earnings for a company growing at the speed of inflation."

At some point, the "safety premium" becomes its own risk. If interest rates stay elevated and bond yields offer 4-5%, dividend investors may not see the appeal of a 2.18% yield that requires taking equity risk.

And that payout ratio of 79% is worth watching. If core earnings do not recover above $3.00 EPS, the company will be paying out more of its earnings than is comfortable. The 4% annual dividend growth rate could slow to 2-3%.

Colgate vs. Its Consumer Staples Peers

| Stock | Yield | P/E | Gross Margin | Revenue Growth | FCF Yield | |---|---|---|---|---|---| | CL | 2.18% | 35.24 | 60.1% | +1.4% | 4.89% | | PG | ~2.4% | ~25 | ~51% | +2-3% | ~4.5% | | KO | 2.71% | 25.69 | ~60% | +1.9% | ~3.5% | | CHD (Church & Dwight) | ~1.1% | ~30 | ~46% | +4% | ~3.5% |

Colgate is the most expensive of the consumer staples Dividend Kings by P/E. You are paying a premium for the margin profile and the global reach.

Compared to Procter & Gamble, CL has better margins but slower growth and a higher P/E. Compared to Coca-Cola, CL has less brand cachet but a stronger free cash flow yield. Church & Dwight offers faster growth but weaker margins.

If you can only own one, P&G probably offers the best balance of value, growth, and yield. But CL is the better pure defensive play.

Our Honest Verdict: HOLD — Fair Value, Not a Bargain

Colgate-Palmolive is a wonderful business trading at a fair price. That is both the good news and the bad news.

The good:

63-year dividend streak is real and growing at 4% annually
60%+ gross margins and $3.6B in FCF are elite — top-tier quality
Ultra-low beta makes this a portfolio anchor during volatility and market panic
DCF suggests the stock is approximately fairly valued at ~$90-100

The bad:

P/E of 35 leaves zero margin of safety for new buyers
Revenue growth under 2% offers little upside catalyst
The 2.18% yield barely beats inflation
You can buy treasury bonds yielding more with zero equity risk
The Filorga write-down shows management is not infallible

If you already own CL, this is a classic hold-forever stock. The dividend will keep growing. The business will keep chugging. Compounding works if you give it time.

If you are looking to initiate a new position, patience is your friend. CL tends to dip during broad market sell-offs (even if less than peers). A pullback to the $75-80 range would represent genuine value and push the FCF yield above 6%. At $92? You are paying full price for the privilege of owning the Quiet King.

Our Rating: HOLD

For an actually undervalued approach, consider Johnson & Johnson which offers a higher yield at a lower multiple, or check our Dividend Kings List for other options trading below fair value.

Ready to Start Your Dividend Portfolio?

Colgate-Palmolive might be a hold right now, but building a diversified dividend portfolio is always a buy. These platforms make it easy to get started with fractional shares:

👉 Open a Moomoo account — Get free stocks when you sign up + professional-grade research tools

👉 Open a Webull account — Commission-free trading with powerful charting and screening tools

Run the Numbers Yourself

Never take anyone's word for it — especially ours. Use these tools to do your own analysis:

🧮 Graham Number Calculator — Calculate fair value for any stock (works best when book value is meaningful)
📊 Piotroski F-Score Calculator — Score financial health from 0-9
📖 Benjamin Graham's 7 Criteria — The classic value investing checklist
💰 How Much Do You Need to Live Off Dividends? — The math behind passive income
📉 What Is a Good Dividend Yield? — Why 2% can be better than 7%

Disclaimer: This article is for educational purposes only. It is not financial advice. We may earn commissions from affiliate links. Always do your own research before investing. Data sourced from StockAnalysis.com as of March 2026.